Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has received a consensus rating of “Hold” from the twenty-five analysts that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $113.75.
Several research firms recently issued reports on MRNA. Singular Research raised shares of Moderna to a “hold” rating in a report on Wednesday, September 23rd. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Evercore raised their price target on Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. JPMorgan Chase & Co. lifted their price objective on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Finally, TD Cowen reissued a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st.
Get Our Latest Analysis on MRNA
Insider Buying and Selling
Institutional Investors Weigh In On Moderna
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CENTRAL TRUST Co raised its stake in shares of Moderna by 36.5% in the 3rd quarter. CENTRAL TRUST Co now owns 172 shares of the company’s stock valued at $33,000 after acquiring an additional 46 shares in the last quarter. Costello Asset Management INC lifted its holdings in Moderna by 7.3% in the 3rd quarter. Costello Asset Management INC now owns 966 shares of the company’s stock worth $186,000 after purchasing an additional 66 shares during the last quarter. Physician Wealth Advisors Inc. boosted its position in Moderna by 8.3% during the third quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock worth $171,000 after purchasing an additional 68 shares during the period. Fortitude Family Office LLC boosted its position in Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after purchasing an additional 77 shares during the period. Finally, Dogwood Wealth Management LLC boosted its position in Moderna by 158.8% during the third quarter. Dogwood Wealth Management LLC now owns 132 shares of the company’s stock worth $25,000 after purchasing an additional 81 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.
Moderna Trading Down 3.4%
Shares of Moderna stock opened at $223.37 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. Moderna has a 1 year low of $22.28 and a 1 year high of $280.80. The company’s fifty day moving average is $201.67 and its two-hundred day moving average is $96.41. The company has a market capitalization of $90.38 billion, a P/E ratio of -31.46 and a beta of 1.16.
Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. The firm’s revenue for the quarter was up 29.2% on a year-over-year basis. Analysts forecast that Moderna will post -5.34 earnings per share for the current year.
Moderna News Summary
Investors following MRNA have been watching these news items:
- Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
- Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article
- Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article
Moderna Company Profile
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Moderna
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
